pipeline.png

Chase’s lead candidate is CPC-201, an oral combination of donepezil, which is an acetylcholinesterase inhibitor (AChEI), and a peripherally acting cholinergic blocker for the treatment of Alzheimer’s disease. CPC-212 and CPC-250 are patch formulations of an AChEI paired with a side-effect modulating pharmaceutical for the treatment of Alzheimer’s and other neurological diseases.